A Phase I, Single-Centre, Double-Blind, Placebo-Controlled, Escalating Single Oral Dose, Safety and Tolerability Clinical Trial With BTA9881 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 08 Apr 2015
At a glance
- Drugs BTA 9881 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Biota Pharmaceuticals
- 16 Oct 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 16 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jan 2008 The expected completion date for this trial is now 1 May 2008 as reported by ClinicalTrials.gov.